This is a searchable database of specificities of 55684 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.
We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.
If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.
If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.
| Inhibitor | Brutto | MW | Action | Reference | Screen Conc | % Activity Remaining |
|---|---|---|---|---|---|---|
| Pirfenidone | C12H11NO | 185.23 | Antifibrotic agent, SAPK |
Kehrer and Margolin (1997) Toxicol. Lett. 90 125 Iyer (1999) J.Pharmacol.Exp.Ther. 289 211 WO2005040758 |
1.00 | 113 |
| PKR Inhibitor | C13H8N4OS | 268.30 | PKR |
Ingrand S (2007) FEBS Lett. 581(23):4473-8 |
1.00 | 52 |
| PKR Inhibitor | C13H8N4OS | 268.30 | PKR |
Ingrand S (2007) FEBS Lett. 581(23):4473-8 |
10.00 | 20 |
| Vemurafenib | C23H18ClF2N3O3S | 489.92 | B-RAF |
Bollag G. (2010) Nature 467 596-9 |
10.00 | 103 |
| Vemurafenib | C23H18ClF2N3O3S | 489.92 | B-RAF |
Bollag G. (2010) Nature 467 596-9 |
1.00 | 102 |
| PRT062607 | C19H23N9O | 393.45 | SYK |
Spurgeon S.E. (2013) J. Pharmacol Exp Ther. 2013 Feb. 344(2) 378-387 |
0.10 | 99 |
| PRT062607 | C19H23N9O | 393.45 | SYK |
Spurgeon S.E. (2013) J. Pharmacol Exp Ther. 2013 Feb. 344(2) 378-387 |
10.00 | 67 |
| PRT062607 | C19H23N9O | 393.45 | SYK |
Spurgeon S.E. (2013) J. Pharmacol Exp Ther. 2013 Feb. 344(2) 378-387 |
1.00 | 97 |
| QNZ | C22H20N4O | 356.40 | NF-κB |
|
10.00 | 85 |
| QNZ | C22H20N4O | 356.40 | NF-κB |
|
1.00 | 100 |